1199589-61-1 Usage
Properties
1. Chemical Formula: C17H13N3O
2. Functional Groups:
Amino group (-NH2)
Nitrile group (-C≡N)
3. Structure:
Pyrrole derivative
Contains a phenoxyphenyl substituent
4. Potential Applications:
Medicinal chemistry
Pharmaceutical development
5. Biological Interactions:
Suitable for interactions with biological targets
Potential biological activities
Structure Description
Contains an amino group (2-amino)
Substituted at position 4 with a phenoxyphenyl group (4-(4-phenoxy-phenyl))
Contains a nitrile group at position 3 (3-carbonitrile)
Applications in Medicinal Chemistry
Potential for drug development
May serve as a lead compound for designing new pharmaceuticals
Need for Further Research
Full potential and uses require further exploration
Additional studies needed to elucidate biological activities and mechanisms of action
This compound presents an intriguing prospect in medicinal chemistry due to its unique structure and potential biological interactions. However, extensive research is necessary to fully understand its capabilities and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1199589-61-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,9,5,8 and 9 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1199589-61:
(9*1)+(8*1)+(7*9)+(6*9)+(5*5)+(4*8)+(3*9)+(2*6)+(1*1)=231
231 % 10 = 1
So 1199589-61-1 is a valid CAS Registry Number.
1199589-61-1Relevant articles and documents
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Paragraph 0042, (2014/06/23)
The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolites, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provided the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. Formula (IV)
